Annals of Oncology Advance Access originally published online on October 25, 2006
Annals of Oncology 2007 18(2):269-274; doi:10.1093/annonc/mdl370
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
gynecologic tumors |
Prognostic significance of stromal versican expression in human endometrial cancer
1 Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
2 Department of Obstetrics and Gynecology, Inner Mongolia Agriculture University Hospital, Huhehaote, China
* Correspondence to: Dr J. Kodama, Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. Tel: +81-862357320; Fax: +81-862259570; E-mail: kodama{at}cc.okayama-u.ac.jp
Background: Versican expression may enhance tumor invasion and metastasis. However, the expression of versican in human endometrial cancer has seldom been characterized. The aim of this study was to investigate versican expression in endometrial cancers.
Patients and methods: We immunohistochemically investigated the expression of versican protein in 167 endometrial cancers and analyzed the correlation with various observed clinicopathological features, including patient outcome.
Results: Stromal versican expression was significantly higher in the advanced-stage (P = 0.010) and high-grade (P = 0.049) cancers, lymph node metastasis (P = 0.012), and ovarian metastasis (P = 0.024). Epithelial versican expression was significantly higher in patients with lymph node metastasis (P = 0.014) and lymph-vascular space involvement (P = 0.014). The disease-free survival (DFS) and overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression (P < 0.0001). Multivariate analysis showed that high stromal versican expression was an independent prognostic factor for DFS and OS.
Conclusions: Versican enrichment of the stroma may be associated with tumor progression in endometrial cancer. Stromal versican expression can serve as an indicator of poor prognosis for patients with endometrial cancer.
Key words: endometrial cancer, prognosis, tumor progression, versican
Received for publication May 12, 2006. Revision received August 23, 2006. Accepted for publication September 6, 2006.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Domenzain-Reyna, D. Hernandez, L. Miquel-Serra, M. J. Docampo, C. Badenas, A. Fabra, and A. Bassols Structure and Regulation of the Versican Promoter: THE VERSICAN PROMOTER IS REGULATED BY AP-1 AND TCF TRANSCRIPTION FACTORS IN INVASIVE HUMAN MELANOMA CELLS J. Biol. Chem., May 1, 2009; 284(18): 12306 - 12317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Soltermann, V. Tischler, S. Arbogast, J. Braun, N. Probst-Hensch, W. Weder, H. Moch, and G. Kristiansen Prognostic Significance of Epithelial-Mesenchymal and Mesenchymal-Epithelial Transition Protein Expression in Non-Small Cell Lung Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7430 - 7437. [Abstract] [Full Text] [PDF]
|
|